Bolt Biotherapeutics BOLT Income Statement (2020-2026)

NASDAQ BOLT
$3.24 -0.07 (-2.11%)
At close: Aug 20, 2026 · 4:00 PM EDT
Income Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity) (Quarter)
1.86M1.87M1.87M1.88M1.88M1.89M1.89M1.90M1.90M1.91M1.91M1.91M1.91M1.92M1.92M1.92M1.92M1.92M1.92M1.93M
Revenue & cost
Revenue (Quarter)
0.75M0.51M0.81M1.39M2.11M1.41M1.83M1.43M2.53M2.09M5.27M1.27M1.14M1.22M1.80M2.17M2.50M0.03M0.01M
Operating items
Research & Development (Quarter)
19.34M22.48M18.39M18.92M18.97M16.84M14.62M15.64M14.95M16.32M16.53M15.43M13.79M11.72M9.51M7.50M6.54M4.99M4.83M5.15M
Selling, General & Administrative (Quarter)
4.94M5.10M6.30M5.53M5.49M5.61M5.62M5.62M5.76M5.53M5.84M4.87M3.80M3.95M3.83M3.52M3.34M3.12M2.80M2.42M
Restructuring Costs (Quarter)
3.56M-0.22M1.48M
Other Operating Expenses (Quarter)
1.47M0.81M
Operating Expenses (Quarter)
24.28M27.58M24.69M24.45M24.46M22.45M20.24M21.27M20.71M21.86M22.37M23.87M17.58M16.92M13.34M11.01M9.87M9.59M7.63M8.38M
Operating Income (Quarter)
-23.53M-27.07M-23.88M-23.06M-22.35M-21.04M-18.41M-19.83M-18.18M-19.77M-17.09M-22.60M-16.44M-16.92M-12.12M-9.21M-7.70M-7.08M-7.60M-8.37M
EBIT (Quarter)
-23.53M-27.07M-23.88M-23.06M-22.35M-21.04M-18.41M-19.83M-18.18M-19.77M-17.09M-22.60M-16.44M-16.92M-12.12M-9.21M-7.70M-7.08M-7.60M-8.37M
Non-operating items
Interest & Investment Income (Quarter)
0.13M-0.68M0.20M0.40M0.09M0.79M1.44M0.01M0.06M6.25M1.61M1.40M0.25M-0.11M1.05M0.60M0.48M2.60M0.28M0.18M
Non Operating Income (Quarter)
0.13M-0.08M0.20M0.40M0.59M1.04M1.44M1.77M1.93M1.86M6.28M1.40M1.27M0.98M1.07M0.65M0.56M0.45M0.36M0.65M
Net income details
EBT (Quarter)
-62.94M-28.99M-27.91M-58.24M-57.77M-21.50M-50.09M-51.77M-48.88M-11.84M-16.69M-21.45M-16.63M-20.55M-12.30M-42.76M-40.07M-8.57M-8.65M-37.05M
Profit After Tax (Quarter)
-23.39M-27.16M-23.68M-22.66M-21.76M-18.61M-16.30M-18.05M-16.26M-18.65M-10.88M-21.20M-15.18M-16.04M-11.04M-8.61M-7.15M-6.63M-7.24M-7.75M
Income from Continuing Operations (Quarter)
-62.94M-28.99M-27.91M-58.24M-57.77M-21.50M-50.09M-51.77M-48.88M-11.84M-16.69M-21.45M-16.63M-20.55M-12.30M-42.76M-40.07M-8.57M-8.65M-37.05M
Consolidated Net Income (Quarter)
-62.94M-28.99M-27.91M-58.24M-57.77M-21.50M-50.09M-51.77M-48.88M-11.84M-16.69M-21.45M-16.63M-20.55M-12.30M-42.76M-40.07M-8.57M-8.65M-37.05M
Income towards Parent Company (Quarter)
-62.94M-28.99M-27.91M-58.24M-57.77M-21.50M-50.09M-51.77M-48.88M-11.84M-16.69M-21.45M-16.63M-20.55M-12.30M-42.76M-40.07M-8.57M-8.65M-37.05M
Net Income towards Common Stockholders (Quarter)
-62.94M-28.99M-27.91M-58.24M-57.77M-21.50M-50.09M-51.77M-48.88M-11.84M-16.69M-21.45M-16.63M-20.55M-12.30M-42.76M-40.07M-8.57M-8.65M-37.05M
Additional items
EPS (Basic) (Quarter)
-33.82-17.45-14.91-31.05-30.69-11.44-26.50-27.35-25.76-6.25-8.76-11.24-8.69-10.76-6.42-22.30-20.88-4.47-4.50-19.27
EPS (Diluted) (Quarter)
-33.83-17.46-15.03-31.23-30.85-11.51-26.59-27.43-25.82-6.26-8.77-11.25-8.70-10.77-6.42-22.30-20.88-4.58-5.15-21.92
Shares Outstanding (Quarter)
1.86M1.66M1.87M1.88M1.88M1.88M1.89M1.89M1.90M1.90M1.91M1.91M1.91M1.91M1.92M1.92M1.92M1.92M1.92M1.92M
Shares Outstanding (Diluted) (Quarter)
1.86M1.66M1.86M1.86M1.87M1.87M1.88M1.89M1.89M1.89M1.90M1.91M1.91M1.91M1.92M1.92M1.92M1.87M1.68M1.69M
EBITDA (Quarter)
-23.53M-27.07M-23.88M-23.06M-22.35M-21.04M-18.41M-19.83M-18.18M-19.77M-17.09M-22.60M-16.44M-16.92M-12.12M-9.21M-7.70M-7.08M-7.60M-8.37M
Interest Expenses (Quarter)
39.54M1.23M4.23M35.58M35.52M1.25M33.11M31.94M30.75M-1.67M1.20M0.26M0.44M3.53M1.24M34.15M32.84M4.09M1.32M28.86M